Charmacy Pharmaceutical Co., Ltd.

SEHK:2289 주식 보고서

시가총액: HK$972.0m

Charmacy Pharmaceutical 미래 성장

Future 기준 확인 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Charmacy Pharmaceutical.

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

Healthcare 수익 성장22.1%
매출 성장률n/a
향후 자기자본 수익률n/a
애널리스트 커버리지

None

마지막 업데이트n/a

최근 미래 성장 업데이트

Recent updates

There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

May 13
There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump

Apr 24
There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump

Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jan 19
Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well

Oct 25
These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well

If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity

Sep 17
If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity

Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?

May 02
Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?

What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Mar 15
What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?

Feb 17
Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?

We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide

Jan 27
We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide

Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture

Jan 09
Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture

What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us

Dec 22
What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us

Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years

Nov 29
Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Charmacy Pharmaceutical 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

SEHK:2289 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (CNY Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
6/30/20244,48252-63-42N/A
3/31/20244,44352-100-69N/A
12/31/20234,40451-137-97N/A
9/30/20234,48074-163-125N/A
6/30/20234,55796-190-153N/A
3/31/20234,36693-77-55N/A
12/31/20224,175903544N/A
9/30/20223,931544451N/A
6/30/20223,688185359N/A
3/31/20223,74120420N/A
12/31/20213,79423-45-20N/A
9/30/20213,9592975111N/A
6/30/20214,12436195241N/A
3/31/20214,05838137186N/A
12/31/20203,9924179131N/A
9/30/20203,81935-100-37N/A
6/30/20203,64529-280-205N/A
3/31/20203,56934-175-101N/A
12/31/20193,49340-704N/A
9/30/20193,55741-3144N/A
6/30/20193,62142784N/A
3/31/20193,77844-2166N/A
12/31/20183,93545-4949N/A
9/30/20184,07546-1226N/A
6/30/20184,21447-196-37N/A
3/31/20184,15546N/A-35N/A
12/31/20174,09645N/A-33N/A
9/30/20173,94654N/A-82N/A
6/30/20173,79663N/A-130N/A
3/31/20173,73360N/A-116N/A
12/31/20163,67056N/A-102N/A
9/30/20163,60547N/A-27N/A
6/30/20163,54038N/A47N/A
3/31/20163,46832N/A120N/A
12/31/20153,39726N/A194N/A
9/30/20153,29931N/A156N/A
6/30/20153,20035N/A119N/A
3/31/20153,10736N/A52N/A
12/31/20143,01436N/A-15N/A
12/31/20132,40122N/A45N/A

애널리스트 미래 성장 예측

수입 대 저축률: Insufficient data to determine if 2289's forecast earnings growth is above the savings rate (2.3%).

수익 vs 시장: Insufficient data to determine if 2289's earnings are forecast to grow faster than the Hong Kong market

고성장 수익: Insufficient data to determine if 2289's earnings are expected to grow significantly over the next 3 years.

수익 대 시장: Insufficient data to determine if 2289's revenue is forecast to grow faster than the Hong Kong market.

고성장 수익: Insufficient data to determine if 2289's revenue is forecast to grow faster than 20% per year.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: Insufficient data to determine if 2289's Return on Equity is forecast to be high in 3 years time


성장 기업 발견